11

22

Ian’s Biography

• BSc & PhD (Physics) and MBA

• OCLI - Optical thin films

• VISION – CMOS imagers

• Terahertz Photonics – Optical Communications Components

• Biosensia – Roadside drugs of abuse testing

• Ambicare – Wearable light sources for skin cancer

33

Company Overview

• Private venture capital backed company

• Spin-out from St Andrews University and Tayside Health Board

• Ambulatory lighting technologies for medical and consumer applications

• ISO 13485 qualified with first product CE marked and launching in Europe

44

Medical: Treatment:Ambulight: PDT

55

Skin Cancer

• Skin cancer incidence growing rapidly

• 15% of UK, 40% of American, 75% of Australian population are affected

• Ambulight: PDT

– Potential to be used in ~ 40% of non-melanoma skin cancer treatments

• Incidence of skin cancer doubling every ten years

USA market data

66

Application of ALA* cream at tumour site*5-aminolevulinic acid (5-ALA)

Illumination of tumour region with high intensity Light sourcePresence of light causes

PP9 to produce singlet Oxygen leading to local cellular destruction within the tumour only

PDT

ALA metabolised to Light sensitive Proto porphyrin PP9 only within the tumourWait 3 hours

• What is Photodynamic Therapy (PDT)?

77

Existing Treatment Techniques

• Conventional Outpatient PDT– Laser / ILED / bulb based light sources

• Large and expensive stationary light sources used– Six hours at clinic as a day patient

– Costly / nurse intensive– Inconvenient for patient and healthcare provider

• Treatment can be uncomfortable for patient

• However, a preferred treatment technique– High tumour selectivity– Curative in 70% + of lesions (after 2 treatments)– Relatively pain free (in ~ 75 % of cases)– Excellent cosmetic result– Non – Invasive– Minimal side effects

88

Ambulight: PDT

• World’s first light emitting sticking plaster to treat non melanoma skin cancer– Low light intensity – Low power consumption allows ambulatory product– Wavelength matched to PDT cream

• Product CE marked and about to launch in Europe• Currently being taken through regulatory approval in the USA, Australia and other

countries• Significant benefits over competing products and methods• Potential to transform patient care by enabling “normal life” during treatment

99

Ambulight: PDT

Device applied at same time as PDT cream

Device worn during normal daily activities

Device disposed

• Typical Device Treatment Cycle

1010

Ambulight PDT: Pilot Clinical Trial

• Shows equivalence to existing PDT treatment methods• > 70% clearance rate• using 1/10th the intensity for 10 times as long

• Reduced pain• Patient testimonials

Patient DiagnosisLesionsize (cm) 1st Rx 2nd Rx Outcome at 6 months

1 Bowens 1.1 Oct '05 Nov '05 Clear

2 Bowens 1.1 Oct '05 Nov '05 Fail peripheral margin

3 SBCC 1.7 Nov '05 Dec '05 Clear

4 Bowens 1.2 Nov '05 Dec '05 Clear

5 SBCC 1.6 Feb '06 March '06 Clear

6 Bowens 0.7 Feb '06 March '06 Clear

7 SBCC 1.5 Feb '06 March '06 Clear

8 Bowens 1.7 Feb '06 April '06 Fail peripheral margins

9 Bowens 1.0 Feb '06 April '06 Clear

10 Bowens 0.6 March '06 April '06 Clear

11 SBCC 1.9 March '06 April '06 Fail peripheral margins

12 Bowens 1.1 April '06 June '06 Clear

1111

Ambulight: PDT

Benefits to healthcare providers

• Changes the way in which doctors can treat skin cancer – Home– Family doctor

• Simple and easy to use• Potentially frees up hospital beds• Less costly• High patient throughput

Benefits to Patients

• More comfortable treatment• Equivalence or improved treatment success rate• Reduced scarring

Transition bulky light sources to small and portable

1212

Economics of treatment

Patient Journey

• GP consultation ( x 1 or more)• Dermatologist consultation ( x 3 or more)• Transport to and from hospital• Local anaesthetic (if pain experienced)• Hospital cubicle / day patient bed space• Nurse time• Other overhead e.g. Health and safety on laser equipment, eye

protection goggles, air coolers for skin• PDT cream cost• Ambulight PDT light source*

• *cost of items highlighted in red can be removed or greatly reduced by introduction of Ambulight PDT light source over conventional light source

1313

How do you build a university technology spin-out?

1414

Migrating Researchers into Entrepreneurs and into Start-Up companies

• IP filing and commercial assessment

• Deciding what you want from it

• Recognise your strength and weaknesses and build a team

• Never be afraid to ask for advice but seek it from multiple sources

• Do your home work and write a good business plan (through collaboration if necessary). Plan your fund raising

• Be prepared for the highs, lows and unknowns.... And hope for a bit of luck on the way

• Why do I love it.... You will never have two days the same

1515

What’s the challenges of interdisciplinary teams?

1616

What’s the challenges of interdisciplinary teams(in healthcare)?

• You have more views to accommodate and manage

• If more people have been involved in the invention then more people looking for a share of the equity (individuals and institutions)– Can take longer to reach agreement on licence contracts or company set up

• You may have more technology monitoring to do to remain competitive in your market place

• In healthcare the time from patent filing to establishing validity of concept in patients can be quite long– Increased cost– Takes longer to establish value; this impacts how you raise finance

1717

info@ambicarehealth.com

Thank you for your attention